Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,078
archived clinical trials in
Major Depression Disorder (MDD)

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  5/23/2013
Teva Investigational Site 603
mi
from 43215
Watertown, MA
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 5/23/2013
Teva Investigational Site 603
mi
from 43215
Watertown, MA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  5/23/2013
Teva Investigational Site 10187
480
mi
from 43215
Brooklyn, NY
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 5/23/2013
Teva Investigational Site 10187
480
mi
from 43215
Brooklyn, NY
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  5/23/2013
Teva Investigational Site 1355
477
mi
from 43215
New York, NY
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 5/23/2013
Teva Investigational Site 1355
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  5/23/2013
Teva Investigational Site 110
469
mi
from 43215
Staten Island, NY
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 5/23/2013
Teva Investigational Site 110
469
mi
from 43215
Staten Island, NY
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  5/23/2013
Teva Investigational Site 614
485
mi
from 43215
Wilmington, NC
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 5/23/2013
Teva Investigational Site 614
485
mi
from 43215
Wilmington, NC
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  5/23/2013
Teva Investigational Site
98
mi
from 43215
Cincinnati, OH
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 5/23/2013
Teva Investigational Site
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  5/23/2013
Teva Investigational Site 013
119
mi
from 43215
Toledo, OH
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 5/23/2013
Teva Investigational Site 013
119
mi
from 43215
Toledo, OH
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  5/23/2013
Teva Investigational Site
849
mi
from 43215
Oklahoma City, OK
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 5/23/2013
Teva Investigational Site
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  5/23/2013
Teva Investigational Site 406
mi
from 43215
Allentown, PA
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 5/23/2013
Teva Investigational Site 406
mi
from 43215
Allentown, PA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  5/23/2013
Teva Investigational Site 403
mi
from 43215
Desoto, TX
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 5/23/2013
Teva Investigational Site 403
mi
from 43215
Desoto, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  5/23/2013
Teva Investigational Site 612
mi
from 43215
Friendswood, TX
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 5/23/2013
Teva Investigational Site 612
mi
from 43215
Friendswood, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  5/23/2013
Teva Investigational Site 1343
1513
mi
from 43215
Salt Lake City, UT
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 5/23/2013
Teva Investigational Site 1343
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  5/23/2013
Teva Investigational Site 1323
2001
mi
from 43215
Kirkland, WA
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 5/23/2013
Teva Investigational Site 1323
2001
mi
from 43215
Kirkland, WA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated:  5/23/2013
Teva Investigational Site 10124
1778
mi
from 43215
Spokane, WA
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Status: Enrolling
Updated: 5/23/2013
Teva Investigational Site 10124
1778
mi
from 43215
Spokane, WA
Click here to add this to my saved trials
Creatine Augmentation in Veterans With SSRI-Resistant Major Depression
Creatine Augmentation in Female & Male Veterans With Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder
Status: Enrolling
Updated:  6/19/2013
George E. Wahlen Veterans Affairs Medical Center
1511
mi
from 43215
Salt Lake City, UT
Creatine Augmentation in Veterans With SSRI-Resistant Major Depression
Creatine Augmentation in Female & Male Veterans With Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder
Status: Enrolling
Updated: 6/19/2013
George E. Wahlen Veterans Affairs Medical Center
1511
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
1985
mi
from 43215
Redondo Beach, CA
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
1985
mi
from 43215
Redondo Beach, CA
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
2091
mi
from 43215
San Jose, CA
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
2091
mi
from 43215
San Jose, CA
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
1981
mi
from 43215
Sherman Oaks, CA
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
1981
mi
from 43215
Sherman Oaks, CA
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
980
mi
from 43215
Hallandale Beach, FL
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
980
mi
from 43215
Hallandale Beach, FL
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
428
mi
from 43215
Smyrna, GA
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
428
mi
from 43215
Smyrna, GA
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
622
mi
from 43215
Prairie Village, KA
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
622
mi
from 43215
Prairie Village, KA
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
337
mi
from 43215
Baltimore, MD
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
337
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
480
mi
from 43215
New York, NY
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
469
mi
from 43215
Staten Island, NY
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
469
mi
from 43215
Staten Island, NY
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
369
mi
from 43215
Raleigh, NC
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
369
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
130
mi
from 43215
Beachwood, OH
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
130
mi
from 43215
Beachwood, OH
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
998
mi
from 43215
Houston, TX
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
998
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
1514
mi
from 43215
Murray, UT
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
1514
mi
from 43215
Murray, UT
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
2001
mi
from 43215
Kirkland, WA
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
2001
mi
from 43215
Kirkland, WA
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
1973
mi
from 43215
Los Angeles, CA
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
1973
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
993
mi
from 43215
Miami, FL
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
411
mi
from 43215
Athens, GA
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
411
mi
from 43215
Athens, GA
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
323
mi
from 43215
Bethesda, MD
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
323
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
618
mi
from 43215
Kansas City, MO
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
618
mi
from 43215
Kansas City, MO
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
444
mi
from 43215
Bridgewater, NJ
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
444
mi
from 43215
Bridgewater, NJ
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
478
mi
from 43215
Brooklyn, NY
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
478
mi
from 43215
Brooklyn, NY
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
89
mi
from 43215
Cincinnati, OH
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
89
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
362
mi
from 43215
Chattanooga, TN
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
362
mi
from 43215
Chattanooga, TN
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
1512
mi
from 43215
American Fork, UT
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
1512
mi
from 43215
American Fork, UT
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
330
mi
from 43215
Burlington, WI
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
330
mi
from 43215
Burlington, WI
Click here to add this to my saved trials
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
Status: Enrolling
Updated:  8/28/2013
University of Texas at Austin
1064
mi
from 43215
Austin, TX
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
Status: Enrolling
Updated: 8/28/2013
University of Texas at Austin
1064
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
Status: Enrolling
Updated:  8/28/2013
University of Texas at Austin Department of Psychology
1065
mi
from 43215
Austin, TX
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
Status: Enrolling
Updated: 8/28/2013
University of Texas at Austin Department of Psychology
1065
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
8-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of LY2940094 Administered Once Daily in Patients With Major Depressive Disorder (MDD)
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
986
mi
from 43215
North Miami, FL
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
8-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of LY2940094 Administered Once Daily in Patients With Major Depressive Disorder (MDD)
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
986
mi
from 43215
North Miami, FL
Click here to add this to my saved trials
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
8-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of LY2940094 Administered Once Daily in Patients With Major Depressive Disorder (MDD)
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
967
mi
from 43215
Oakland Park, FL
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
8-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of LY2940094 Administered Once Daily in Patients With Major Depressive Disorder (MDD)
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
967
mi
from 43215
Oakland Park, FL
Click here to add this to my saved trials
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
8-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of LY2940094 Administered Once Daily in Patients With Major Depressive Disorder (MDD)
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
868
mi
from 43215
University Park, FL
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
8-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of LY2940094 Administered Once Daily in Patients With Major Depressive Disorder (MDD)
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
868
mi
from 43215
University Park, FL
Click here to add this to my saved trials
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
8-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of LY2940094 Administered Once Daily in Patients With Major Depressive Disorder (MDD)
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
622
mi
from 43215
Prairie Village, KA
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
8-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of LY2940094 Administered Once Daily in Patients With Major Depressive Disorder (MDD)
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
622
mi
from 43215
Prairie Village, KA
Click here to add this to my saved trials
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
8-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of LY2940094 Administered Once Daily in Patients With Major Depressive Disorder (MDD)
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
1333
mi
from 43215
Albuquerque, NM
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
8-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of LY2940094 Administered Once Daily in Patients With Major Depressive Disorder (MDD)
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
1333
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials